(Q52946591)

9 May 2018

title

The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. (English)

1 reference

9 May 2018

1 reference

1

1 reference

9 May 2018

Mohammad Abufaraj

3

1 reference

9 May 2018

Alberto Briganti

11

Alberto Briganti

1 reference

9 May 2018

10

Francesco Montorsi

1 reference

9 May 2018

Shahrokh Shariat

2

Shahrokh F Shariat

1 reference

9 May 2018

Andrea Salonia

9

Andrea Salonia

1 reference

9 May 2018

Francesco Soria

4

Francesco Soria

1 reference

9 May 2018

Tobias Klatte

5

Tobias Klatte

1 reference

9 May 2018

author name string

Giovanni La Croce

6

1 reference

9 May 2018

Agostino Mattei

7

1 reference

9 May 2018

Rocco Damiano

8

1 reference

9 May 2018

Renzo Colombo

12

1 reference

9 May 2018

Andrea Gallina

13

1 reference

9 May 2018

publication date

5 December 2016

1 reference

9 May 2018

published in

Urologic Oncology

1 reference

9 May 2018

volume

35

1 reference

9 May 2018

issue

4

1 reference

9 May 2018

page(s)

151.e17-151.e23

1 reference

9 May 2018

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Characterization of perioperative infection risk among patients undergoing radical cystectomy: Results from the national surgical quality improvement program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2016.11.003

10.1016/J.UROLONC.2016.11.003

7 January 2021

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018